Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study. - Rose, P.G.; Java, J.; Morgan, M.A.; Secord, A.A.; Kesterson, J.; Stehman, F.B.; Warshal, D.P.; Creasman, W.T.; Hanjani, P.; Morris, R.T.; Copeland, L.J. (Gynecologic Oncology, 2016)